Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Theravance Biopharma (TBPH) Invested Capital (2016 - 2025)

Historic Invested Capital for Theravance Biopharma (TBPH) over the last 13 years, with Q3 2025 value amounting to $232.7 million.

  • Theravance Biopharma's Invested Capital rose 2533.05% to $232.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $232.7 million, marking a year-over-year increase of 2533.05%. This contributed to the annual value of $175.5 million for FY2024, which is 1758.26% down from last year.
  • Latest data reveals that Theravance Biopharma reported Invested Capital of $232.7 million as of Q3 2025, which was up 2533.05% from $224.8 million recorded in Q2 2025.
  • Over the past 5 years, Theravance Biopharma's Invested Capital peaked at $480.6 million during Q3 2022, and registered a low of -$361.6 million during Q1 2021.
  • For the 5-year period, Theravance Biopharma's Invested Capital averaged around $75.6 million, with its median value being $193.7 million (2024).
  • Its Invested Capital has fluctuated over the past 5 years, first plummeted by 12892.75% in 2021, then soared by 25449.59% in 2022.
  • Theravance Biopharma's Invested Capital (Quarter) stood at -$321.6 million in 2021, then skyrocketed by 237.36% to $441.8 million in 2022, then plummeted by 51.79% to $213.0 million in 2023, then fell by 17.58% to $175.5 million in 2024, then surged by 32.55% to $232.7 million in 2025.
  • Its last three reported values are $232.7 million in Q3 2025, $224.8 million for Q2 2025, and $166.0 million during Q1 2025.